(Q35124915)

6 August 2017

title

An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting (English)

1 reference

6 August 2017

1 reference

Nawaz Hack

1

0 references

Nikolaus R McFarland

object named as

Nikolaus McFarland

10

0 references

Michael S. Okun

object named as

Michael S Okun

12

0 references

author name string

Sarah M Fayad

2

1 reference

6 August 2017

Erin H Monari

3

1 reference

6 August 2017

Umer Akbar

4

1 reference

6 August 2017

Angela Hardwick

5

1 reference

6 August 2017

Ramon L Rodriguez

6

1 reference

6 August 2017

Irene A Malaty

7

1 reference

6 August 2017

Janet Romrell

8

1 reference

6 August 2017

Aparna A Wagle Shukla

9

1 reference

6 August 2017

Herbert E Ward

11

1 reference

6 August 2017

language of work or name

English

0 references

publication date

19 March 2014

1 reference

6 August 2017

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

e91545

1 reference

Creative Commons Attribution 4.0 International

6 August 2017

copyright license

start time

19 March 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

The practical management of cognitive impairment and psychosis in the older Parkinson's disease patient

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Substantia nigra depigmentation and exposure to encephalitis lethargica.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Parkinson disease psychosis: Update

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Long-duration Parkinson's disease: role of lateralization of motor features

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

What are the issues facing Parkinson's disease patients at ten years of disease and beyond? Data from the NPF-QII study

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Atypical antipsychotic drugs in the treatment of Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

An update expert opinion on management and research strategies in Parkinson's disease psychosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

New Zealand community pharmacists' views of their roles in meeting medicine-related needs for people with mental illness.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Hallucinations and psychosis in Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Incidence and remaining lifetime risk of Parkinson disease in advanced age.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

When a Parkinson's disease patient starts to hallucinate

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Early dopaminergic drug-induced hallucinations in parkinsonian patients

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Visual Hallucinations and Delirium During Treatment with Amantadine (Symmetrel)

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

High rates and the risk factors for emergency room visits and hospitalization in Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Delirium with manic and psychotic features associated with amantadine.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Brain regions associated with cognitive impairment in patients with Parkinson disease: quantitative analysis of cerebral blood flow using 123I iodoamphetamine SPECT.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Motor profile and drug treatment of nursing home residents with Parkinson's disease.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Nonmotor complications of Parkinson disease

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Transitioning patients taking clozapine from the public to private/GP shared-care setting: barriers and criteria.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Transient amantadine-induced musical hallucinations in a patient with Parkinson's disease

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Isolated delusional syndrome in Parkinson's Disease

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Altered mental status in a transplant patient. Amantadine toxicity

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Plasma amantadine concentrations in patients with Parkinson's disease

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Longitudinal outcome of Parkinson's disease patients with psychosis

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3960134

Quetiapine as an Alternative to Clozapine in the Treatment of Dopamimetic Psychosis in Patients with Parkinson's Disease

27 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0091545

Clozapine and risperidone treatment of psychosis in Parkinson's disease

21 January 2018

1 reference

12 December 2020

Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis

1 reference

12 December 2020

Motor and non-motor symptoms of 1453 patients with Parkinson's disease: prevalence and risks

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Amantadine-induced psychosis in a young healthy patient

1 reference

12 December 2020

Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease.

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0091545

Identifiers

DOI

1 reference

6 August 2017

0 references

1 reference

6 August 2017

1 reference